Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Veradigm ( (MDRX) ).
On August 20, 2025, Veradigm‘s Board of Directors approved an amendment to extend the company’s Stockholder Rights Plan, initially adopted in February 2024, to February 20, 2026. This amendment raises the triggering threshold for beneficial ownership from 10% to 20% for non-passive investors, ensuring that all stockholders can realize the full potential value of their investment. The extension reflects the Board’s assessment of ongoing risks and conditions similar to those at the plan’s inception, with the intention to terminate the plan once the company is current in its financial reporting and relists its shares on a national exchange, expected in 2026.
The most recent analyst rating on (MDRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Veradigm stock, see the MDRX Stock Forecast page.
More about Veradigm
Veradigm is a healthcare technology company that provides data-driven solutions and technology for healthcare providers, payers, and the biopharma markets. The company leverages its platforms, data, expertise, and connectivity to deliver advanced insights and solutions.
Average Trading Volume: 98,321
Technical Sentiment Signal: Sell
Current Market Cap: $788.5M
See more insights into MDRX stock on TipRanks’ Stock Analysis page.